Earnings Feed
Start Free
Artiva Biotherapeutics, Inc.·4

Jul 14, 7:00 PM ET

RA Capital Healthcare Fund LP 4

Research Summary

AI-generated summary

Updated

Artiva (ARTV) 10% Owner RA Capital Buys Shares

What Happened

  • RA Capital Management, L.P. (a reported 10% owner) made open-market purchases of Artiva Biotherapeutics (ARTV) stock. The filing reports a 7/10/2026 purchase of 15,102 shares at a weighted average price of $8.97 (≈ $135,465) and a 7/13/2026 purchase of 6,552 shares at a weighted average price of $8.94 (≈ $58,575). Total acquired: 21,654 shares for roughly $194,040. Purchases are generally viewed as a bullish signal (versus sales), though institutional purchases can reflect portfolio management decisions.

Key Details

  • Transaction dates and prices:
    • 2026-07-10: 15,102 shares at $8.97 (weighted average); reported price range for these trades: $8.89–$9.00 (footnote F1).
    • 2026-07-13: 6,552 shares at $8.94 (weighted average); reported price range for these trades: $8.89–$8.95 (footnote F4).
  • Shares owned after the transaction: not specified in the provided filing excerpt.
  • Filing date: 2026-07-14. Because one purchase occurred on 2026-07-10, the consolidated Form 4 filing appears late for that earlier trade (typically Form 4s are due within two business days); the 7/13 trade was filed promptly on 7/14.
  • Notable footnotes:
    • The trades were executed across multiple transactions (hence weighted average prices and reported ranges; RA Capital can provide per-trade detail on request — F1, F4).
    • Purchases were made by RA Capital-managed vehicles (the Adviser manages the Fund, Nexus Fund, Nexus III, and an Account). Specific holdings are reported as held directly by those vehicles (see footnotes F2–F7). The adviser and certain principals disclaim direct beneficial ownership except for pecuniary interests (F2).
  • Other remark: Laura Stoppel, a Principal of the Adviser, serves on Artiva’s board of directors (as noted in the filing).

Context

  • This is institutional buying by an investment manager and its funds/accounts—not an individual executive making a personal trade. Institutional purchases can reflect conviction by the manager or routine portfolio adjustments; the filing itself is factual and does not state intent. If you follow insider activity, purchases by a 10% holder are notable but should be considered alongside other signals (company news, fundamentals, and larger trading activity).